Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab.

× No keyword cloud information.

28 in total

1. Hydrocephalus during natalizumab treatment.

Authors: Chiara Zecca; Claudio Städler; Claudio Gobbi
Journal: Neurol Sci Date: 2010-05-08 Impact factor: 3.307

2. Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome.

Authors: L Prosperini; G Borriello; F Fubelli; F Marinelli; Carlo Pozzilli
Journal: Neurol Sci Date: 2011-01 Impact factor: 3.307

Review 3. [Oral fingolimod in multiple sclerosis: therapeutic modulation of the sphingosine-1-phosphate system].

Authors: O Aktas; J Ingwersen; B Kieseier; P Küry; R Hohlfeld; H-P Hartung
Journal: Nervenarzt Date: 2011-02 Impact factor: 1.214

4. Monoclonal antibodies in multiple sclerosis treatment: current and future steps.

Authors: Claire L Helliwell; Alasdair J Coles
Journal: Ther Adv Neurol Disord Date: 2009-07 Impact factor: 6.570

Review 5. Translational research in neurology and neuroscience 2010: multiple sclerosis.

Authors: Olaf Stüve; Bernd C Kieseier; Bernhard Hemmer; Hans-Peter Hartung; Amer Awad; Elliot M Frohman; Benjamin M Greenberg; Michael K Racke; Scott S Zamvil; J Theodore Phillips; Ralf Gold; Andrew Chan; Uwe Zettl; Ron Milo; Ellen Marder; Omar Khan; Todd N Eagar
Journal: Arch Neurol Date: 2010-07-12

Review 6. Progressive multifocal leukoencephalopathy in HIV-1 infection.

Authors: Paola Cinque; Igor J Koralnik; Simonetta Gerevini; Jose M Miro; Richard W Price
Journal: Lancet Infect Dis Date: 2009-10 Impact factor: 25.071

7. Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors.

Authors: Jonathan Zurawski; Ashley Flinn; Lindsay Sklover; Jacob A Sloane
Journal: J Neurol Date: 2016-05-18 Impact factor: 4.849

8. Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents.

Authors: Carlo Piccinni; Chiara Sacripanti; Elisabetta Poluzzi; Domenico Motola; Lara Magro; Ugo Moretti; Anita Conforti; Nicola Montanaro
Journal: Eur J Clin Pharmacol Date: 2009-10-17 Impact factor: 2.953

Review 9. Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.

Authors: Clemens Warnke; Heinz Wiendl; Hans-Peter Hartung; Olaf Stüve; Bernd C Kieseier
Journal: Drug Des Devel Ther Date: 2010-07-21 Impact factor: 4.162

10. Review of teriflunomide and its potential in the treatment of multiple sclerosis.

Authors: Clemens Warnke; Gerd Meyer zu Hörste; Hans-Peter Hartung; Olaf Stüve; Bernd C Kieseier
Journal: Neuropsychiatr Dis Treat Date: 2009-06-10 Impact factor: 2.570